Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent
US11407831B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 29, 2018 |
| Grant date | Aug 9, 2022 |
| Priority date | — |
| Expiry date | Oct 29, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition including a compound represented by the formula (I) or a pharmacologically acceptable salt thereof wherein two R moieties each independently are a C1-3 alkyl group or are groups bonded to each other to form a C2-5 alkylene group; A is an optionally substituted C6-10 aryl group or an optionally substituted heteroaryl group; and R1, R2 and R3 each independently are an optionally substituted linear or branched C1-4 alkyl group, wherein the pharmaceutical composition is administered in combination with an immunotherapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.